Objective. MIA (melanoma inhibitory activity) is correlated with metastasis in patients with malignant melanoma. As MIA is not only produced by melanoma cells, but also by differentiated chondrocytes, we examined whether serum levels of MIA are correlated with inflammation and/or joint destruction in rheumatic diseases.
Rheumatoid arthritis (RA) is characterized by progressive some 19 with no known homology to other proteins [1] [2] [3] [4] . In non-malignant tissues, MIA expression is predomindestruction of affected joints, reflected by an invasive growth of aggressive synovial tissue into adjacent cartilage antly seen in developing and mature cartilage [5, 6 ] , whereas in malignancies, elevated serum levels are preand bone. Although advanced laboratory and radiological technologies exist, it is difficult to evaluate joint destruction dominantly found in metastatic melanoma, and to a lesser extent in ovarian, pancreatic and breast cancer [7] . due to the lack of markers indicating the presence and extent of joint destruction. In addition, in early disease, In addition, there is evidence that enhanced serum concentrations of MIA indicate the degree of metastasis the differential diagnosis of RA vs other joint-destructive rheumatic diseases such as psoriatic arthritis, HLA in melanoma patients [7, 8] . Thus, we examined whether MIA might also be a marker for cartilage and bone B27-associated arthritides and gout, and numerous nonjoint-destructive rheumatic diseases such as systemic lupus degradation in rheumatic diseases, supported by the fact that MIA is produced by chondrocytes [5] . We further erythematosus (SLE), frequently appears difficult.
Similar to RA, invasive growth of tumours is associated examined whether enhanced concentrations of MIA are specific for joint-destructive vs non-destructive rheumwith the destruction of tissue matrix. Recently, a novel protein, named MIA (melanoma inhibitory activity), atic diseases, and evaluated correlations for clinical and laboratory parameters and MIA. derived from metastatic melanoma cell lines, has been characterized. The secreted form is a small 11 kDa protein of 131 amino acids encoded by a single gene on chromo-(PsA), 12 patients with HLA B27-associated oligoarthritis, 12 patients with osteoarthritis (OA), 12 patients with gout, 10 patients with systemic sclerosis (SSc) and 10 patients with relapsing polychondritis (RP) visiting the out-patient clinic of the Division of Rheumatology and Clinical Immunology of the Department of Internal Medicine I of the University of Regensburg. None of the patients suffered from malignant melanoma. Controls consisted of 100 patients with metastatic melanoma and 120 healthy individuals. Serum samples were aliquoted and stored immediately at −20°C. In addition, erythrocyte sedimentation rate ( ESR), C-reactive protein (CRP), rheumatoid factor (RF ), titre of antinuclear antibodies, and red and white blood cell counts were evaluated on the day of the visit. X-rays were taken at the time of blood sampling and examined by two experienced rheumatologists and one radiologist. X-rays were scored destruction vs no destruction according to the presence of multiple cysts, 1A12 and 2F7, provided by Boehringer Mannheim) were raised and conjugated to horseradish peroxidase and biotin, respectively. Ten microlitres of serum or fibroblasts were obtained from biopsies of synovial tissue of patients with RA who met the criteria of the American standard were incubated with 200 ml of reagent containing biotinylated 2F7 antibody and horseradish College of Rheumatology, and from patients with longterm OA. After enzymatic digestion, fibroblasts were peroxidase-1A12 antibody in a streptavidin-coated 96-well plate for 45 min with continuous shaking. After grown in culture flasks in DMEM-Cellgro (Mediatech, Washington, DC, USA) containing 10% fetal calf serum washing three times in phosphate-buffered saline (PBS), 200 ml of 2,2∞-azino-di-(3)-ethylbenz-thiazoline sulphon-(Gibco Life Technologies, Grand Island, NY, USA). Cells were cultured for 3-5 passages, stained for ate (Boehringer Mannheim) were added to the wells and measured colorimetrically at 405 nm. Standardization fibroblast markers by immunocytochemistry (>95% could be stained positively for the fibroblast enzyme was performed using solutions of purified MIA derived from stably MIA-transfected Chinese hamster ovary prolyl 4-hydroxylase and none were positive for the macrophage marker CD68 or the neutrophil marker cells in a range from 0.1 to 50 ng/ml. The standard curve was calculated in a linear fashion. All serum cathepsin G; data not shown), and tested for mycoplasmas. At 70-80% confluency, supernatant from 10 samples and standards were measured in duplicate and results never varied more than 5%. MIA serum concendifferent RA and five different OA cultures was examined for the presence of MIA. trations of the different patient groups were compared with the serum concentrations of healthy individuals Statistics and patients with metastatic melanoma.
To evaluate the specificity of the ELISA system with For comparison of MIA serum concentrations, the Mann-Whitney test for non-paired parameters was regard to interfering factors in the sera of patients with RA, e.g. the presence of RF, we performed titration applied. For evaluation of the association between MIA in sera and RF, ESR, CRP and joint destruction, experiments using increasing amounts of non-labelled second antibody 2F7 (Fig. 1 ).
Fisher's exact test was performed. P values of <0.05 were regarded as significant.
Cell culture
As fibroblasts are known to produce MIA following Results stimulation with mitogens [3, 5] , we established cell cultures to exclude that enhanced MIA serum values Using the ELISA test system, healthy individuals showed MIA serum concentrations ranging from 1.8 to are due to production by synovial fibroblasts. Synovial 7.6 ng/ml. MIA values of healthy individuals followed serum concentrations were also RF negative, and only 8/22 patients (32%) with normal MIA serum concentraa Gaussian distribution, and were age independent [7] . Applying 3 .. to baseline of healthy individuals, tions had a positive RF. Thus, statistical analysis using Fisher's exact test revealed that enhanced MIA serum MIA values of at least 6.5 ng/ml ( ELISA cut-off ) were regarded as elevated. As compared to healthy indiconcentrations were associated significantly with RF positivity. viduals, patients with metastatic melanoma showed elevated MIA serum concentrations ranging from 7.1 to In addition, 18/24 patients (75%) who had enhanced MIA serum concentrations also showed radiographic 82 ng/ml with an average of 18.8 ng/ml ( Table 1) .
In contrast, MIA serum concentrations of patients signs of joint destruction at the time of presentation independent of the duration of the disease, whereas only with rheumatic diseases varied considerably, and increased serum concentrations were found only in 6/24 (25%) patients with normal MIA serum concentrations showed no radiographic signs of joint destruction. patients with joint-destructive rheumatic diseases.
A total of 24/46 of the patients with RA, 8/29 of the On the other hand, 15/22 patients (68%) having normal MIA serum concentrations showed no radiographic patients with PsA, 6/12 of the patients with HLA B27-associated oligoarthritis and 3/11 of the patients signs of joint destruction, and only 7/22 patients (32%) with normal MIA serum concentrations showed radiowith OA showed enhanced MIA serum concentrations. Interestingly, the highest values were found in patients graphic signs of joint destruction ( Table 2 ). Statistical analysis using Fisher's exact test revealed, similar to the with RA, ranging from 2.9 to 42.8 ng/ml. In addition, one patient with highly active RA and severe joint association with RF outlined above, that enhanced MIA serum concentrations were associated significantly with destruction showed an MIA serum concentration of 100 ng/ml. Except for one patient with PsA showing an radiographic signs of joint destruction. Of interest, both of the non-RA patients with MIA MIA serum concentration of 14.8 ng/ml and one patient with HLA B27-associated oligoarthritis with an MIA serum concentrations >10 ng/ml showed signs of radiographic joint destruction. In contrast to the associations serum concentration of 11.7 ng/ ml, patients of all other groups did not have MIA serum concentrations with RF and joint destruction, enhanced MIA serum concentrations were not associated with ESR, CRP, >10 ng/ml. In the titration experiments using increasing amounts of the second antibody 2F7, detection of MIA leucocyte counts and antinuclear antibodies in these patients. In addition, cultured RA as well as OA synovial could be completely inhibited, therefore indicating no interference of serum proteins, e.g. RF, with measurefibroblasts did not produce MIA (data not shown). ment of MIA concentrations (data not shown).
Of the potentially joint-destructive rheumatic diseases, Discussion the mean MIA serum concentration was 10.3 ± 10.2 ng/ml (range 2.9-100 ng/ml ) for RA patients, The results of our experiments indicate that increased serum concentrations of MIA are not limited to patients 6.6 ± 3.0 ng/ml (range 2.1-11.7 ng/ml ) for patients with HLA B27-associated oligoarthritis, 5.2 ± 1.4 ng/ml with malignant disease, but can also be measured in patients with rheumatic diseases, especially in patients (range 3.3-7.8 ng/ml ) for OA patients and 4.8 ± 3.2 (range 0-14.8 ng/ml ) for patients with PsA. However, with RA. In malignant melanoma, most recently MIA has been as compared to serum concentrations of healthy blood donors, only patients with RA had significantly elevated established as a reliable serum parameter for metastasis [7, 8] . In these patients, MIA is produced by malignant MIA serum concentrations (P < 0.05). Interestingly, although having an active flare of the disease at the time melanoma cells, and serum concentrations correlate with the occurrence of metastasis. Conversely, in this study, of presentation, none of the 11 patients with gout showed elevated MIA serum concentrations (mean none of the patients showing normal MIA concentrations developed metastasis in the follow-up period of 2.6 ± 1.0 ng/ml; range 1.0-3.8 ng/ml ).
In contrast, none of the patients with non-joint-1 yr. Although the pathophysiological function of MIA in melanoma patients still remains to be elucidated, destructive rheumatic diseases, such as SLE, SSc and RP, showed increased MIA serum concentrations (one there is preliminary evidence that MIA supports metastasis by cell rounding and decreased adhesion of melapatient with SLE had a borderline MIA serum concentration of 6.6 ng/ml ). MIA serum concentrations of noma cells (A. K. Bosserhoff, personal communication). In healthy organisms, MIA expression is limited to SLE patients ranged from 1.2 to 6.6 ng/ml with a mean of 4.4 ± 1.3 ng/ml, SSc patients ranged from 1.1 to cartilaginous tissue. Both in developing as well as in mature cartilage, MIA mRNA and protein can be 4.5 ng/ml with a mean of 3.5 ± 2.8 ng/ml, and RP patients ranged from 1.4 to 5.5 ng/ml with a mean of detected [5, 6 ] . In chondrogenesis, MIA is expressed in the axial and peripheral skeleton, and in mature cartilage 3.4 ± 2.7 ng/ml. All data are summarized in Table 1 and Fig. 2 .
chondrocytes are known to be the only source for MIA synthesis. This was supported by the fact that, in the In patients with RA, 19/24 patients (79%) who had elevated serum MIA concentrations were also positive present study, cultured RA (and OA) synovial fibroblasts, which are known to be involved in joint for RF, whereas only 5/24 patients (21%) showing elevated MIA serum concentrations were RF negative.
destruction, in particular at the sites of invasion of the proliferating synovial tissue into adjacent cartilage [9, Conversely, 14/22 patients (64%) having normal MIA process of joint destruction in these patients, and is only in part due to a passive release of MIA from necrotic or apoptotic chondrocytes. has been found, which could be upregulated by IL-1b P = 0.007 (Fisher's exact test).
and tumour necrosis factor alpha [24] . Of interest, distinct mechanisms of matrix degradation are similar in metastasis of melanoma and rheumatoid 10], did not produce enhanced amounts of MIA. This is in contrast to cartilage oligomeric matrix protein joint destruction. Matrix metalloproteinases and cysteine proteases (e.g. collagenases and cathepsins B, D, H (COMP), which has been considered as a marker for cartilage destruction, but is produced by both chondroand L), as well as the proteases plasmin and cathepsin D, which are found in considerable amounts at the sites cytes and synovial fibroblasts [11] .
Little is known about the regulation of MIA synthesis of articular degradation in rheumatoid joints [10, 25, 26 ] , are also key molecules in metastatic pathways in and the physiological properties of MIA in cartilage metabolism, but there are indications that transcription melanoma patients [27] [28] [29] [30] [31] [32] . Similar to RA, degradation of type IV collagen is dependent on the presence of of MIA might be dependent in part on nuclear transcription factors such as NFkB [3, 5] . As nuclear transcripcollagenase [33], whereas matrix metalloproteinase-2 contributed to early tumour progression in melanoma tion factors including NFkB are also activated in various pathways leading to joint destruction in RA [12] [13] [14] , lesions [34] . Of interest, fibroblast-dependent matrix degradation by cathepsin B, which is a major pathway we examined the presence of MIA in serum of patients with different rheumatic diseases and its association in rheumatoid joint destruction [9, 10, 35], can also be detected in fibroblasts derived from melanoma tissue with laboratory parameters and radiological joint destruction. [29] . Although angiogenesis is not only crucial for malignant diseases, but also plays a considerable role in Interestingly, only patients with RA showed serum levels of MIA as elevated as the majority of the the initiation and perpetuation of inflammation in rheumatoid synovium, current knowledge does not melanoma patients, whereas in all patients with other rheumatic diseases, only slightly elevated MIA serum support the hypothesis that angiogenesis contributes to elevated MIA serum concentrations in RA synovium, levels were detected. Therefore, it can be speculated that MIA is released actively from chondrocytes during the as previous experiments revealed that endothelial cells 
